EGFR and carcinoma: Using cMab U36 labeled with 211Astatine showed reliable results in treating rats with HNSCC; on the other hand, combining this radioimmunotherapy with cetuximab revealed better results in controlling carcinoma and drew attention to interactions between CD44v6 and epidermal growth factor receptor (EGFR).170